THYMOSIN BETA 4 FOR TREATING MULTIPLE SCLEROSIS

Description

Field of the Invention

[0001] The present invention relates to the field of treating or preventing tissue deterioration, injury or damage due to multiple-sclerosis (MS).

Description of the Background Art

[0002] Neuro-degenerative diseases, muscular-degenerative diseases and neuro-muscular-degenerative diseases are debilitating diseases that can destroy memory, brain functions, muscle functions and other physiological functions of a subject. Such diseases may be genetic, or result from exposure by a subject to factors in the environment, contaminated food, and the like. Such diseases may include Alzheimer's disease, multiple sclerosis (MS), Lou Gehrig's disease (amytrophic lateral sclerosis or ALS), Parkinson's disease, spinal muscular atrophy (SMA), myasthenia gravis, autism, muscular dystrophy, transmissible spongiform encephalopathies (TSEs) including bovine spongiform encephalopathy (BSE), and the like.

[0003] Muscular dystrophies are genetic disorders characterized by progressive muscle wasting and weakness that begin with microscopic changes in the muscle. As muscles degenerate overtime, the person's muscle strength declines.

[0004] Duchenne muscular dystrophy (DMD) is one of a group of muscular dystrophies characterized by the enlargement of muscles. DMD is one of the most prevalent types of muscular dystrophy and is characterized by rapid progression of muscle degeneration that occurs early in life. All are X-linked and affect mainly males - an estimated 1 in 3500 boys worldwide.

[0005] The gene for DMD, found on the X chromosome, encodes a large protein - dystrophin. Dystrophin is required inside muscle cells for structural support; it is thought to strengthen muscle cells by anchoring elements of the internal cytoskeleton to the surface membrane. Without it, the cell membrane becomes permeable, so that extracellular components enter the cell, increasing the internal pressure until the muscle cell "explodes" and dies. The subsequent immune response can add to the damage.

[0006] Becker muscular dystrophy (BMD) is a much milder version of DMD. Its onset is usually in the teens or early adulthood, and the course is slower and far less predictable than that of DMD.

[0007] In the U.S., there are over 84,000 patients with degenerative muscular dystrophy diseases.

[0008] There remains a need in the art for methods of treatment for treating, preventing, inhibiting or reducing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or for restoring tissue adversely affected by said disease.

[0009] The present invention satisfies this need by providing a compostition for use in a method of treating or reducing deterioration of, injury or damage to tissue due to multiple sclerosis, and the use of the composition in the manufacture of a medicament for treating or reducing deterioration of, injury or damage to tissue due to multiple sclerosis.

Summary of the invention

[0010] Subject-matter of the present invention is the use of a composition comprising thymosin beta 4 in the manufacture of a medicament for treating or reducing deterioration of, injury or damage to tissue due to multiple sclerosis (MS) as claimed in claim 1.

[0011] Subject-matter of the present invention is also a composition comprising thymosin beta 4 for use in a method of treating or reducing deterioration of, injury or damage to tissue due to multiple sclerosis (MS) as claimed in claim 8.

[0012] Embodiments of the present invention are claimed in the respective dependent claims.

DETAILED DESCRIPTION OF THE INVENTION

[0013] Without being bound to any specific theory, actin-sequestering peptides such as thymosin beta 4 (Tβ4 or TB4) and other agents including actin-sequestering peptides or peptide fragments containing amino acid sequence LKKTET or LKKTNT or conservative variants thereof, promote reversal or prevention of tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease.

[0014] Thymosin beta 4 was initially identified as a protein that is up-regulated during endothelial cell migration and differentiation in vitro. Thymosin beta 4 was originally isolated from the thymus and is a 43 amino acid, 4.9 kDa ubiquitous polypeptide identified in a variety of tissues. Several roles have been ascribed to this protein including a role in a endothelial cell differentiation and migration, T cell differentiation, actin sequestration, vascularization and wound healing.

[0015] The invention is applicable to multiple sclerosis. This disease may be associated with inflammatory disorders.

[0016] In accordance with one embodiment, the invention is a composition for use in a method of treatment for treating or reducing tissue deterioration, injury or damage due to multiple sclerosis in a subject. The method comprises administering to a subject in need of such treatment an effective amount of a composition comprising thymosin β4. The composition may, in addition, comprise a peptide agent, which may be a polypeptide comprising amino acid sequence LKKTET or LKKTNT, or a conservative variant thereof having neuro-, muscular-, and/or neuro-muscular-degenerative disease-inhibiting activity, Tβ4 isoforms, analogues or derivatives, including KLKKTET, LKKTETQ, N-terminal variants of Tβ4, C-terminal variants of Tβ4 and antagonists of Tβ4, oxidized Tβ4, or an antimicrobial agent other than thymosin beta 4 or oxidized Tβ4.

[0017] Compositions which may be used in accordance with the present invention include Tymosin β4 (Tβ4), and optionally also include peptide agents such as Tβ4 isoforms, analogues or derivatives, including oxidized Tβ4, N-terminal variants of Tβ4, C-terminal variants of Tβ4 and antagonists of Tβ4, polypeptides or peptide fragments comprising or consisting essentially of the amino acid sequence LKKTET or conservative variants thereof, having neuro-, muscular-, and/or neuro-muscular-degenerative disease-inhibiting activity. International Application WO00/06190 (Serial No. PCT/US99/17282)discloses isoforms of Tβ4. as well as amino acid sequence LKKTET and conservative variants thereof. International Application Serial No. PCT/GB99/00833 (WO 99/49883), discloses oxidized Thymosin β4. Although the present invention is described hereinafter with respect to Tβ4, it is to be understood that Tβ4 may be used in a combination with amino acid sequence LKKTET or LKKTNT, peptides and fragments comprising or consisting essentially of LKKTET or LKKTNT, conservative variants thereof having neuro-, muscular-, and/or neuro-muscular-degenerative disease-inhibiting activity, and/or Tβ4 isoforms, analogues or derivatives, including N-terminal variants of Tβ4, C-terminal variants of Tβ4 and antagonists of Tβ4 or oxidizedTβ4.

[0018] In one embodiment, the invention provides a composition comprising Tβ4 for use in a method of treatment for treating or reducing tissue deterioration, injury or damage due to multiple sclerosis, in a subject, comprising administering to a subject in need of such treatment an effective amount of the composition. The composition may, in addition, comprise a peptide agent comprising amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, in said tissue, so as to inhibit said tissue deterioration, injury or damage due to multiple sclerosis.

[0019] In another embodiment, the invention provides the use of a composition in the manufacture of a medicament for treating or reducing tissue deterioration, injury or damage due to multiple sclerosis, in a subject, wherein treating comprises administering to a subject in need of such treatment an effective amount of the composition comprising Tβ4. The composition may, in addition, comprise a peptide agent other than Tβ4 comprising amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, in said tissue, so as to inhibit said tissue deterioration, injury or damage due to multiple sclerosis. The method of treatment for treating or reducing tissue deterioration, injury or damage due to a multiple sclerosis, in a subject, involves contacting the tissue with an effective amount of the composition which contains Tβ4. As non-limiting examples, the tissue may be selected from neural and/or muscular tissue of said subject. The contacting may be directly or systemically. Examples of direct administration include, for example, contacting the tissue, by direct application or inhalation, with a solution, lotion, salve, gel, cream, paste, spray, suspension, dispersion, hydrogel, ointment, or oil comprising Tβ4. Systemic administration includes, for example, intravenous, intraperitoneal, intramuscular injections of a composition containing Tβ4 in a pharmaceutically acceptable carrier such as water for injection.

[0020] Tβ4 and peptide agents which may be used in addition to Tβ4, as described herein, may be administered in any effective amount. For example, a peptide agent as described herein may be administered in dosages within the range of about 0.0001-1,000,000 micrograms, more preferably in amounts within the range of about 0.1-5,000 micrograms, most preferably within the range of about 1-30 micrograms.

[0021] A composition for use in accordance with the present invention can be administered daily, every other day, every other week, every other month, etc., with a single application or multiple applications per day of administration, such as applications 2, 3, 4 or more times per day of administration.

[0022] Many Tβ4 isoforms have been identified and have about 70%, or about 75%, or about 80% or more homology to the known amino acid sequence of Tβ4. Such isoforms include, for example, Tβ4, Tβ9, Tβ10, Tβ11, Tβ12, Tβ13, Tβ14 and Tβ15. Similar to Tβ4, the Tβ10 and Tβ15 isoforms have been shown to sequester actin. Tβ4, Tβ10 and Tβ15, as well as these other isoforms share an amino acid sequence, LKKTET or LKKTNT, that appears to be involved in mediating actin sequestration or binding. Although not wishing to be bound by any particular theory, the activity of peptide agents as described herein may be due, at least in part, to the anti-inflammatory activity of such agents. Tβ4 also can modulate actin polymerization (e.g. -thymosins appear to depolymerize F-actin by sequestering free G-actin). Tβ4's ability to modulate actin polymerization may be due to its ability to bind to or sequester actin via the LKKTET or LKKTNT sequence. Thus, as with Tβ4, other proteins which are anti-inflammatory and/or bind or sequester actin, or modulate actin polymerization, including Tβ4 isoforms having the amino acid sequence LKKTET or LKKTNT, are likely to be effective, alone or in a combination with Tβ4, as set forth herein.

[0023] Peptide agents as described herein, can prevent and/or limit the apoptic death of brain and other neurovascular cells and tissue by upregulating metabolic and signaling enzymes such as the phosphatidylinositol 3-kinase (P13-K)/Akt (protein kinase β) pathway. Upregulating P13-K)/Akt and downstream phosphorylated Bad and proline rich Akt survival kinase protects neuronal cells. In addition peptide agents as described herein, such as Tβ4 and Tβ4 isoforms or oxidized forms of Tβ4 by virtue of their ability to downregulate inflammatory cytokines such as IL-18 and chemokines such as IL-8 and enzymes such as caspace 2, 3, 8 and 9 protects neuronal cells and facilitates healing of nervous tissue.

[0024] Peptide agents as described herein, can decrease inflammatory chemokine, cytokine and capase activity.

[0025] Peptide agents as described herein, can prevent neurotoxicity in the brain and spinal cord by preventing glutamate induced neurotoxicity. Uncontrolled release of glutamate, an excitatory neurotransmitter, from damaged brain and nervous tissues is a primary mediator of mitochondrial dysfunction and energy mechanisms in the cell which results in several inflammatory reactions, mechanical stress altered trophic signals and death of affected nervous cells and tissues.

[0026] Thus, known LKKTET or LKKTNT peptides as described herein, including Tβ4 isoforms, such as Tβ4^ala, Tβ9, Tβ10, Tβ11, Tβ12, Tβ13, Tβ14 and Tβ15, as well as Tβ4 isoforms not yet identified, will be useful in a method of treating or reducing deteroration of, injury or damage to tissue due to multiple sclerosis, including a i method practiced in a subject. Therefore, pharmaceutical compositions comprising Tβ4, for the use disclosed herein may comprise also Tβ4 isoforms Tβ4^ala, Tβ9, Tβ10, Tβ11, Tβ12, Tβ13, Tβ14 and Tβ15, and a pharmaceutically acceptable carrier.

[0027] In addition, other agents or proteins have anti inflammatory activity and/or actin sequestering or binding capability, or that can mobilize actin or modulate actin polymerization, as demonstrated in an appropriate sequestering, binding, mobilization or polymerization assay, or identified by the presence of an amino acid sequence that mediates actin binding, such as LKKTET or LKKTNT, for example. Such proteins may include gelsolin, vitamin D binding protein (DBP), profilin, cofilin, depactin, Dnasel, vilin, fragmin, severin, capping protein, β-actinin and acumentin, for example. Pharmaceutical compositions for the use disclosed herein may comprise, in addition to Tβ4, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, depactin, Dnasel, vilin, fragmin, severin, capping protein, β-actinin and acumentin as set forth herein. Thus, a composition comprising Tβ4 for the use disclosed herein may also include a polypeptide comprising the amino acid sequence LKKTET or LKKTNT and conservative variants thereof.

[0028] As used herein, the term "conservative variant" or grammatical variations thereof denotes the replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the replacement of a hydrophobic residue such as isoleucine, valine, leucine or methionine for another, the replacement of a polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, and the like.

[0029] Tβ4 has been localized to a number of tissue and cell types and thus, agents which stimulate the production of an LKKTET or LKKTNT peptide such as Tβ4 or another peptide agent as described herein, can be added to a composition for the claimed use to effect production a peptide agent from a tissue and/or a cell. Such stimulating agents may include members of the family of growth factors, such as insulin-like growth factor (IGF-1), platelet derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor beta (TGF-β), basic fibroblast growth factor (bFGF), thymosin β1 (Tβ1) and vascular endothelial growth factor (VEGF). More preferably, the stimulating agent is transforming growth factor beta (TGF-β) or other members of the TGF-β superfamily.

[0030] In accordance with this disclosure subjects are treated with the composition comprising Tβ4, wherein the composition may also comprise a stimulating agent that stimulates production in the subject of a peptide agent as defined herein. Additionally, other agents that assist in reduction of tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restoring tissue adversely affected by said disease may be added to the composition along with a Tβ4. For example, and not by way of limitation, a peptide agent as described herein alone or in combination can be added in combination with any one or more of the following agents: antibiotics, VEGF, KGF, FGF, PDGF, TGF-β, IGF-1, IGF-2, IL-1, prothymosin β and/or thymosin β1 in an effective amount.

[0031] The pharmaceutical composition comprising Tβ4 for the use disclosed herein the compositions may comprise a therapeutically effective amount of a further peptide agent as described herein in a pharmaceutically acceptable carrier. The actual dosage or reagent, formulation or composition that provides treatment may depend on many factors, including the size and health of a subject. However, persons of ordinary skill in the art can use teachings describing the methods and techniques for determining clinical dosages as disclosed in WO 00/06190 (PCT/US99/17282), supra, and the references cited therein, to determine the appropriate dosage to use.

[0032] Suitable formulations may include Tβ4 at a concentration within the range of about 0.001 - 50% by weight, more preferably within the range of about 0.01 - 0.1% by weight, most preferably about 0.05% by weight.

[0033] The therapeutic approaches described herein involve various routes of administration or delivery of Tβ4, including any conventional administration techniques (for example, but not limited to, direct administration, local injection, inhalation, or systemic administration), to a subject. The methods and compositions using or containing Tβ4 may be formulated into pharmaceutical compositions by admixture with pharmaceutically acceptable non-toxic excipients or carriers.

[0034] The composition for the use described herein may include also antibodies which interact with, enhance or inhibit a peptide agent as described herein. Antibodies which consist essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibody preparations are suitable. Monoclonal antibodies are made from antigen containing fragments of the protein by methods well known to those skilled in the art as disclosed in WO 00/06190 (PCT/US99/17282), supra. The term antibody as used in this invention is meant to include monoclonal and polyclonal antibodies.

[0035] Described is also a method of treating a subject by administering an effective amount of stimulating agent which modulates gene expression. The term "modulate" refers to inhibition or suppression of expression when a peptide agent as described herein is over expressed, and induction of expression when a peptide agent as described herein is underexpressed. The term "effective amount" means that amount of stimulating agent which is effective in modulating gene expression of a peptide agent as described herein, resulting in reducing the symptoms of tissue deterioration, injury or damage due to multiple scelorsis. A stimulating agent which modulates gene expression of a peptide agent as described herein may be a polynucleotide, for example. The polynucleotide may be an antisense, a triplex agent, or a ribozyme. For example, an antisense directed to the structural gene region or to the promoter region of a peptide agent as described herein may be utilized. The stimulating agent which modulates gene expression of a peptide agent as described herein may also be a small interfering RNAs (siRNAs).

[0036] Described is further a method for utilizing compounds that modulate activity of a peptide agent as described herein. Compounds that affect activity of a peptide agent as described herein (e.g., antagonists and agonists) include peptides, peptidomimetics, polypeptides, chemical compounds, minerals such as zincs, and biological agents.

[0037] A method for screening for a stimulating agent as described herein, comprises contacting a tissue exhibiting neuro-, muscular-, and/or neuro-muscular-degenerative disease, with a candidate compound; and measuring activity in said tissue of an LKKTET or LKKTNT peptide, wherein an increase of activity of said peptide in said tissue, compared to a level of activity of said peptide in a corresponding tissue lacking said candidate compound, indicates that said compound is capable of inducing said stimulating agent.

SEQUENCE LISTING

[0038] 

<110> Regenerx Biopharmaceuticals, Inc.

<120> Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to a Neuro-, Muscular- or Neuro-Muscular-Degenerative Disease, or Restore Tissue Adversely Affected by Said Disease

<130> K 70 562/7 Kr-ns

<140> PCT/US2006/001255
<141> 2006-01-13

<150> US 60/643,307
<151> 2005-01-13

<160> 4

<170> PatentIn version 3.3

<210> 1
<211> 6
<212> PRT
<213> human, rat, mouse, cat, calf, pig, sheep, horse, chicken, gecko,
xenopus laevis, rainbow trout, perch, whale, scallop, sea urchin

<400> 1

<210> 2
<211> 6
<212> PRT
<213> human, rat

<400> 2

<210> 3
<211> 7
<212> PRT
<213> human, rat, mouse, cat, calf, pig, sheep, horse, chicken, gecko,
xenopus laevis, rainbow trout, perch, whale, scallop, sea urchin

<400> 3

<210> 4
<211> 7
<212> PRT
<213> human, rat, mouse, cat, calf, pig, sheep, horse, chicken, gecko,
xenopus laevis, rainbow trout, perch, whale, sea urchin

<400> 4

Claims

1. Use of a composition comprising Thymosin β4 in the manufacture of a medicament for treating or reducing deterioration of, injury or damage to tissue due to multiple sclerosis (MS).

2. The use of claim 1 wherein said Thymosin β4 is at a dosage within a range of about 1-30 micrograms.

3. The use of claim 1 wherein said Thymosin β4 is for direct administration, or for intravenous, intraperitoneal, intramuscular, subcutaneous, inhalation, transdermal or oral administration.

4. The use of claim 1 wherein said composition is for systemic administration.

5. The use of claim 1 wherein said composition is for direct administration.

6. The use of claim 1 wherein said medicament is in a form of a solution, gel, creme, paste, lotion, spray, suspension, dispersion, salve, hydrogel or ointment.

7. The use of claim 1 wherein said Thymosin β4 is a recombinant or synthetic polypeptide.

8. A composition comprising Thymosin β4 for use in a method of treating or reducing deterioration of, injury or damage to tissue due to multiple sclerosis (MS).

9. The composition for use according to claim 8, wherein said Thymosin β4 is at a dosage within a range of about 1-30 micrograms.

10. The composition for use according to claim 8, wherein said Thymosin β4 is for direct administration, or for intravenous, intraperitoneal, intramuscular, subcutaneous, inhalation, transdermal or oral administration.

11. The composition for use according to claim 8, wherein said composition is for systemic administration.

12. The composition for use according to claim 8, wherein said composition is for direct administration.

13. The composition for use according to claim 8, wherein said composition is in a form of a solution, gel, creme, paste, lotion, spray, suspension, dispersion, salve, hydrogel or ointment.

14. The composition for use according to claim 8, wherein said Thymosin β4 is a recombinant or synthetic polypeptide.

Ansprüche

1. Verwendung einer Zusammensetzung, die Thymosin β4 aufweist, bei der Herstellung eines Arzneimittels zur Behandlung oder Verringerung einer Beeinträchtigung, Verletzung oder Schädigung von Gewebe aufgrund von Multipler Sklerose (MS).

2. Verwendung nach Anspruch 1, wobei das Thymosin β4 bei einer Dosierung in einem Bereich von etwa 1 bis 30 μg liegt.

3. Verwendung nach Anspruch 1, wobei das Thymosin β4 zur unmittelbaren Verabreichung oder zur intravenösen, intraperitonealen, intramuskulären, subkutanen, Inhalations-, transdermalen oder oralen Verabreichung ist.

4. Verwendung nach Anspruch 1, wobei die Zusammensetzung zur systemischen Verabreichung ist.

5. Verwendung nach Anspruch 1, wobei die Zusammensetzung zur unmittelbaren Verabreichung ist.

6. Verwendung nach Anspruch 1, wobei das Arzneimittel in einer Form einer Lösung, eines Gels, einer Creme, einer Paste, einer Lotion, eines Sprays, einer Suspension, einer Dispersion, einer Salbe, eines Hydrogels oder eines Unguentums ist.

7. Verwendung nach Anspruch 1, wobei das Thymosin β4 ein rekombinantes oder synthetisches Polypeptid ist.

8. Zusammensetzung aufweisend Thymosin β4 zur Verwendung bei einem Verfahren zur Behandlung oder Verringerung einer Beeinträchtigung, Verletzung oder Schädigung von Gewebe aufgrund von Multipler Sklerose (MS).

9. Zusammensetzung zur Verwendung nach Anspruch 8, wobei das Thymosin β4 bei einer Dosierung in einem Bereich von etwa 1 bis 30 µg liegt.

10. Zusammensetzung zur Verwendung nach Anspruch 8, wobei das Thymosin β4 zur unmittelbaren Verabreichung oder zur intravenösen, intraperitonealen, intramuskulären, subkutanen, Inhalations-, transdermalen oder oralen Verabreichung ist.

11. Zusammensetzung zur Verwendung nach Anspruch 8, wobei die Zusammensetzung zur systemischen Verabreichung ist.

12. Zusammensetzung zur Verwendung nach Anspruch 8, wobei die Zusammensetzung zur unmittelbaren Verabreichung ist.

13. Zusammensetzung zur Verwendung nach Anspruch 8, wobei die Zusammensetzung in einer Form einer Lösung, eines Gels, einer Creme, einer Paste, einer Lotion, eines Sprays, einer Suspension, einer Dispersion, einer Salbe, eines Hydrogels oder eines Unguentums ist.

14. Zusammensetzung zur Verwendung nach Anspruch 8, wobei das Thymosin β4 ein rekombinantes oder synthetisches Polypeptid ist.

Revendications

1. Utilisation d'une composition comprenant de la thymosine β4 dans la fabrication d'un médicament destiné au traitement ou à la réduction d'une détérioration, d'une lésion ou d'un endommagement d'un tissu dû à la sclérose en plaques (SEP).

2. Utilisation selon la revendication 1, dans laquelle ladite thymosine β4 est à un dosage au sein d'une plage d'environ 1 à 30 microgrammes.

3. Utilisation selon la revendication 1, dans laquelle ladite thymosine β4 est destinée à une administration directe, ou pour une administration intraveineuse, intrapéritonéale, intramusculaire, sous-cutanée, par inhalation, transdermique ou orale.

4. Utilisation selon la revendication 1, dans laquelle ladite composition est destinée à une administration systémique.

5. Utilisation selon la revendication 1, dans laquelle ladite composition est destinée à une administration directe.

6. Utilisation selon la revendication 1, dans laquelle ledit médicament est sous une forme de solution, gel, crème, pâte, lotion, pulvérisation, suspension, dispersion, baume, hydrogel ou pommade.

7. Utilisation selon la revendication 1, dans laquelle ladite thymosine β4 est un polypeptide recombinant ou synthétique.

8. Composition comprenant de la thymosine β4 pour une utilisation dans un procédé de traitement ou de réduction d'une détérioration, d'une lésion ou d'un endommagement d'un tissu dû à la sclérose en plaques (SEP).

9. Composition pour une utilisation selon la revendication 8, dans laquelle ladite thymosine β4 est à un dosage au sein d'une plage d'environ 1 à 30 microgrammes.

10. Composition pour une utilisation selon la revendication 8, dans laquelle ladite thymosine β4 est destinée à une administration directe, ou pour une administration intraveineuse, intrapéritonéale, intramusculaire, sous-cutanée, par inhalation, transdermique ou orale.

11. Composition pour une utilisation selon la revendication 8, dans laquelle ladite composition est destinée à une administration systémique.

12. Composition pour une utilisation selon la revendication 8, dans laquelle ladite composition est destinée à une administration directe.

13. Composition pour une utilisation selon la revendication 8, dans laquelle ladite composition est sous une forme de solution, gel, crème, pâte, lotion, pulvérisation, suspension, dispersion, baume, hydrogel ou pommade.

14. Composition pour une utilisation selon la revendication 8, dans laquelle ladite thymosine β4 est un polypeptide recombinant ou synthétique.